Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Double-masked, Randomized Study to Compare the Safety and Efficacy of the OM3 Tear Formulation With REFRESH OPTIVE® ADVANCED Unit Dose for 3 Months in Patients With Dry Eye Disease

NCT02553772 is registered in ClinicalTrials.gov with Allergan as lead sponsor.

NCT NCT02553772
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02553772 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Double-masked, Randomized Study to Compare the Safety and Efficacy of the OM3 Tear Formulation With REFRESH OPTIVE® ADVANCED Unit Dose for 3 Months in Patients With Dry Eye Disease
Lead sponsor
Allergan
Phase
Phase 3
Overall status
Completed
Start date
January 6, 2016
Completion date
September 9, 2016
Enrollment
242 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

dry eye syndromes